抗凝药物治疗静脉血栓栓塞症争议与共识

Controversy and consensus on the treatment of venous thromboembolism with anticoagulant drugs

静脉血栓栓塞症(VTE)包括深静脉血栓形成(DVT)和肺动脉栓塞(PE),是同一疾病在不同阶段和身体不同部位的两种表现形式。VTE是仅次于心脏病和中风后的第三大常见心血管疾病死亡原因。美国每年>900000例病人发生症状性VTE,除带来巨大的医疗负担外,其中300000例病人死于PE。1949年,抗凝被作为首选治疗方法引入我国后,至今仍占据VTE一线治疗地位。然而,虽然到目前为止我国已经在VTE的诊治中积累了丰富经验,但依然存在一些问题尚待研究和解决。

Venous thromboembolism(VTE),including of deep vein thrombosis(DVT)and pulmonary embolism(PE),are two manifestations of the same disease in different stages and different parts of the body.VTE in the third most common cause of cardiovascular death after heart attack and stroke.VTE is responsible for the hospitalization of at least 900,000 Americans annually and represents a significant healthcare burden with 300,000 of them died in PE.In 1949,anticoagulation was first introduced as the preferred treatment of VTE and remained the first-line treatment for VTE today.However,although we have so far accumulated rich experience in the diagnosis and treatment of VTE,there are still some problems that need to be further studied and resolved.